NewEdge Advisors’s Definium Therapeutics DFTX Stock Holding History

NewEdge Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$125	Sell	7 -133	-95%	-$2.26K	﹤0.01%	4080
2025 Q4	$1.87K	Sell	140 -2	-1%	-$25	﹤0.01%	3896
2025 Q3	$1.67K	Hold	142	–	–	﹤0.01%	3812
2025 Q2	$921	Hold	142	–	–	﹤0.01%	3728
2025 Q1	$831	Sell	142 -6	-4%	-$43	﹤0.01%	3653
2024 Q4	$1.03K	Hold	148	–	–	﹤0.01%	3560
2024 Q3	$842	Hold	148	–	–	﹤0.01%	3543
2024 Q2	$1.07K	Hold	148	–	–	﹤0.01%	3459
2024 Q1	$1.39K	Hold	148	–	–	﹤0.01%	3443
2023 Q4	$542	Hold	148	–	–	﹤0.01%	3528
2023 Q3	$463	Hold	148	–	–	﹤0.01%	3263
2023 Q2	$528	Buy	148 +133	+887%	+$459	﹤0.01%	3311
2023 Q1	$48	Hold	15	–	–	﹤0.01%	3363
2022 Q4	$0	Buy	+15	New	+$42	﹤0.01%	4164

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NewEdge Advisors's DFTX Position: Q1 2026 in Review

NewEdge Advisors reduced its Definium Therapeutics (DFTX) stake by 95% in Q1 2026, selling an estimated $2.26K and leaving 7 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

NewEdge Advisors first reported a position in DFTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.87K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

NewEdge Advisors held 7 shares of Definium Therapeutics worth $125 as of Q1 2026.
NewEdge Advisors sold 133 Definium Therapeutics shares in Q1 2026, an estimated $2.26K.
Definium Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4080 holding.
NewEdge Advisors first reported a position in Definium Therapeutics in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's Definium Therapeutics position peaked at $1.87K in Q4 2025.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.